Syros Pharmaceuticals, Inc. (SYRS)

Market Cap	7.77M
Revenue (ttm)	386,000
Net Income (ttm)	-97.82M
Shares Out	26.81M
EPS (ttm)	-2.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,003,732
Open	0.290
Previous Close	0.277
Day's Range	0.249 - 0.300
52-Week Range	0.183 - 8.170
Beta	1.59
Analysts	Hold
Price Target	3.00 (+934.48%)
Earnings Date	Oct 31, 2024

About SYRS

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 30, 2016
• Employees: 68
• Stock Exchange: NASDAQ
• Ticker Symbol: SYRS
• Website: https://www.syros.com

Financial Performance

In 2023, Syros Pharmaceuticals's revenue was $9.94 million, a decrease of -33.23% compared to the previous year's $14.88 million. Losses were -$164.57 million, 73.9% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for SYRS stock is "Hold." The 12-month stock price forecast is $3.0, which is an increase of 934.48% from the latest price.

Price Target

$3.0

(934.48% upside)

Analyst Consensus: Hold